Fractional shares
Get dividend payments
Global stock markets soared in response to the news that American pharmaceuticals company Pfizer (PFE) has developed a vaccine, tested on 43,500 people, which it claims is 90% effective.
On the day of the announcement, Pfizer's share price rose 15%, before falling back and closing 7% up on the previous day. Other industries reacted positively to the news, with global economic hopes seemingly pinned on the vaccine.
Both exchange rates and share prices fluctuate in real time, so the costs estimated here should be considered as a guide only. They don't factor in spreads, which can be hard to pin down. Always refer to the platform itself for availability and pricing.
Quantity of shares
Platform | Finder Score | Account fee | Min. initial deposit | Trade cost | Link |
---|---|---|---|---|---|
4.3 ★★★★★ |
£0 | $100 | £406.77 |
Go to siteCapital at risk
|
|
4.4 ★★★★★ |
£0 | £1 | £407.74 |
Go to siteCapital at risk
|
|
4.4 ★★★★★ |
£0 | £0 | £405.76 |
Go to siteCapital at risk
|
|
4.4 ★★★★★ |
£0 | £0 | £405.76 |
Go to siteCapital at risk
|
|
4.2 ★★★★★ |
£0 (0.45% for funds) | £1 | £419.73 |
Go to siteCapital at risk
|
|
4.4 ★★★★★ |
0% - 0.25% | £100 | N/A |
Go to siteCapital at risk
|
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Buying shares in just one company is generally considered a riskier bet than investing in a range of investments - AKA a "diversified portfolio". Experts generally recommend holding a mix of investments in specific assets and funds. Funds are ready-made portfolios of multiple companies' shares (potentially including Pfizer), and the idea is that drops in the value of one constituent company's share price might be offset by rises in others.
Pfizer is a major part of the NYSE, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).
ETF | Icon | 5-year performance (to August 2024) | 1-year performance (to August 2024) | Link to invest |
---|---|---|---|---|
Invesco S&P 500 (SPXP) | 94.07% | 22.23% | Invest with XTBCapital at risk | |
Xtrackers S&P 500 Swap (XSPX) | 93.77% | 22.24% | Invest with XTBCapital at risk | |
iShares Core S&P 500 (CSP1) | 91.84% | 21.98% | Invest with XTBCapital at risk | |
HSBC S&P 500 (HSPX) | 80.38% | 20.63% | Invest with XTBCapital at risk | |
Vanguard S&P 500 (VUSA) | 79.29% | 20.60% | Invest with XTBCapital at risk | |
SPDR S&P 500 ETF (SPX5) | 79.17% | 20.61% | Invest with XTBCapital at risk |
Review technicals and fundamentals to help you determine if now's a good time for you to invest.
View Pfizer's price performance, share price volatility, historical data and technicals.
Historical closes compared with the last close of $25.56
1 week (2024-11-26) | -12.68% |
---|---|
1 month (2024-11-03) | -13.36% |
3 months (2024-09-03) | -16.93% |
6 months (2024-06-03) | 3.59% |
1 year (2023-12-03) | -11.92% |
2 years (2022-12-03) | -38.24% |
3 years (2021-12-03) | -32.61% |
5 years (2019-12-03) | -9.63% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Pfizer P/E ratio, PEG ratio and EBITDA.
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Pfizer's shares trade at around 0x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Pfizer's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2188. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Pfizer's PEG ratio in relation to those of similar companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $10 billion (£7.9 billion).
The EBITDA is a measure of Pfizer's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Canopy Growth? We explain how and compare a range of providers that can give you access to many brands, including Canopy Growth.
Ever wondered how to buy shares in Green Thumb Industries? We explain how and compare a range of providers that can give you access to many brands, including Green Thumb Industries.
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
Ever wondered how to buy shares in Genesis Healthcare? We explain how and compare a range of providers that can give you access to many brands, including Genesis Healthcare.
Ever wondered how to buy shares in Allergy Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Allergy Therapeutics.
Ever wondered how to buy shares in 4D pharma? We explain how and compare a range of providers that can give you access to many brands, including 4D pharma.
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
Thinking about buying shares in Evgen Pharma? We explain how to do it and compare a range of providers who will give you access to global markets.
Ever wondered how to buy shares in Intuitive Surgical? We explain how and compare a range of providers that can give you access to many brands, including Intuitive Surgical.
Ever wondered how to buy shares in Stryker? We explain how and compare a range of providers that can give you access to many brands, including Stryker.